Press Releases
|
|
 = Add Release to Briefcase |
|
| Sep 8, 2010 |
Infinity Pharmaceuticals to Present at Two Upcoming Conferences |
|
| |
CAMBRIDGE, Mass., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Rodman & Renshaw Annual Global Investment Conference in New York on Wednesday, September 15, 2010 at 11:40 a.m. EDT.
In addition, Infinity will be presenting at the UBS Global Life Sciences Conference in New York on Wednesda...
|
|
| Aug 4, 2010 |
Infinity Highlights R&D Progress and Announces Second Quarter 2010 Financial Results |
|
| |
CAMBRIDGE, Mass., Aug. 4, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results. Developments since the beginning of the second quarter include:
acquis...
|
|
| Jul 29, 2010 |
Infinity to Present at BMO Healthcare Conference |
|
| |
CAMBRIDGE, Mass., July 29, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that Vito J. Palombella, Chief Scientific Officer, will present a company overview at the BMO 10th Annual Focus on Health Care Conference on Thursday, August 5, 2010 at 10:45 a.m. E...
|
|
| Jul 28, 2010 |
Infinity Announces Second Quarter 2010 Results Conference Call |
|
| |
CAMBRIDGE, Mass., July 28, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, announced today that management will host a conference call on Wednesday, August 4, 2010 at 8:30 a.m. EDT. In the conference call, management will review recent research and development and busines...
|
|
| Jul 8, 2010 |
Infinity and Intellikine Enter Agreement to Develop Oral Therapies Targeting PI3 Kinase Delta, Gamma |
|
| |
Infinity Uses Scientific Expertise and Financial Strength to Enter New Therapeutic AreaIntellikine Retains Strategic Development and Commercial Rights in Oncology in Deal Valued Up to $488 Million
CAMBRIDGE, Mass. and LA JOLLA, Calif., July 8, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and...
|
|
| Jun 24, 2010 |
Infinity Initiates Second Clinical Trial of IPI-493, Its Oral Hsp90 Chaperone Inhibitor |
|
| |
CAMBRIDGE, Mass., June 24, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies. This multi-center study is the second clinical tr...
|
|
| Jun 4, 2010 |
Infinity Reports Results From Phase 2 Clinical Trial of IPI-504 in Non-Small Cell Lung Cancer |
|
| |
CAMBRIDGE, Mass., June 4, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activit...
|
|
| Jun 2, 2010 |
Infinity to Present at Jefferies Global Life Sciences Conference |
|
| |
CAMBRIDGE, Mass., June 2, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that Adelene Q. Perkins, President and Chief Executive Officer, will present a company overview at the Jefferies 2010 Global Life Sciences Conference on Wednesday, June 9, 2010 at 3:...
|
|
| May 24, 2010 |
Infinity Announces Addition to Senior Leadership Team |
|
| |
CAMBRIDGE, Mass., May 24, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that Winselow S. Tucker, Jr. has joined Infinity as vice president, marketing, with responsibility for bringing commercial insights to the company's product development decisions and...
|
|
| May 20, 2010 |
Infinity to Present Data From Its Anti-Cancer Programs at ASCO Meeting |
|
| |
CAMBRIDGE, Mass., May 20, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that data from its Hsp90 chaperone and Hedgehog pathway inhibitor programs will be presented during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held in...
|
|
| May 18, 2010 |
Infinity Announces Senior Management Promotion |
|
| |
CAMBRIDGE, Mass., May 18, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced the promotion of Vito J. Palombella, Ph.D. to Chief Scientific Officer, with responsibility for Infinity's drug discovery and pre-clinical development activities and leadership over ...
|
|
| May 6, 2010 |
Infinity Reports R&D Highlights and Announces First Quarter 2010 Financial Results |
|
| |
CAMBRIDGE, Mass., May 6, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today reported recent research and development (R&D) highlights and announced first quarter 2010 financial results.
"Infinity is using its financial strength to aggressively develop its clinical pi...
|
|
| Apr 29, 2010 |
Infinity Announces May 6 Webcast of First Quarter 2010 Financial Results Conference Call |
|
| |
CAMBRIDGE, Mass., April 29, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, announced today that management will host a conference call on Thursday, May 6, 2010 at 4:30 p.m. EDT. In the conference call, management will review recent research and development and business h...
|
|
| Apr 21, 2010 |
Infinity Initiates Randomized Clinical Trial of IPI-926 in Pancreatic Cancer and Reports New Preclinical Data at AACR |
|
| |
-- Infinity Advances Hedgehog Pathway Inhibitor Into Later Clinical Development ---- New Preclinical Data in Several Cancer Indications Further Support Broad Therapeutic Potential of IPI-926 --
CAMBRIDGE, Mass., April 21, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company,...
|
|
| Apr 8, 2010 |
Infinity to Present New Preclinical Data From Its Hedgehog Pathway Inhibitor Program at AACR Meeting |
|
| |
CAMBRIDGE, Mass., April 8, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today announced that members of its scientific teams will be reporting preclinical data from its novel Hedgehog pathway inhibitor program -- an emerging area of cancer research -- during the 2010 A...
|
|
| Mar 10, 2010 |
Infinity's Innovative Hedgehog Pathway Inhibitor Program to be Highlighted at Upcoming Conferences |
|
| |
-- Julian Adams, Ph.D., President of R&D and CSO, to Present at New York City Academy of Sciences' "Hedgehog Pathway in Cancer" Symposium ---- Infinity Scientists Also to Discuss Hedgehog Pathway and Data at Biorbis Cancer Stem Cells Meeting and EMBO Workshop on Hedgehog Signaling --
CAMBRIDGE, Mass., March 10, 2010 (GLOBE NEWSWIRE) -- Infinity ...
|
|
| Mar 2, 2010 |
Infinity to Present at Cowen Health Care Conference |
|
| |
CAMBRIDGE, Mass., March 2, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Gerald E. Quirk, Esq., Vice President Corporate Affairs and General Counsel, will present a company overview at the 30th Annual Cowen Health Care Conference on Tuesday, ...
|
|
| Feb 23, 2010 |
Infinity Announces Presentations at Upcoming Lung Cancer Meeting |
|
| |
CAMBRIDGE, Mass., Feb. 23, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that presentations featuring two of its clinical candidates will be made at the 10th Annual Targeted Therapies of the Treatment of Lung Cancer meeting to be held February 24-...
|
|
| Feb 10, 2010 |
Infinity Initiates Clinical Development of Its Fourth Drug Candidate and Announces 2009 Financial Results |
|
| |
Clinical Investigation Initiated for IPI-940 With Broad Potential in Neuropathic and Inflammatory Pain
Financially Strong With Sufficient Capital to Fund Its Operating Plan Into 2013
CAMBRIDGE, Mass., Feb. 10, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative drug discovery and development company, today a...
|
|
| Feb 3, 2010 |
Infinity Announces 2009 Financial Results Conference Call |
|
| |
CAMBRIDGE, Mass., Feb. 3, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that management will host a conference call on Wednesday, February 10, 2010 at 4:30 p.m. EST. In the conference call, management will review recent research and development an...
|
|
|
For historical Infinity Pharmaceuticals announcements, please contact Gerald Quirk.
|
|
